<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875391</url>
  </required_header>
  <id_info>
    <org_study_id>Charite2019-Oxytocin-Study</org_study_id>
    <nct_id>NCT03875391</nct_id>
  </id_info>
  <brief_title>The Effect of Oxytocin on the Consolidation of Trauma-Associated Memories</brief_title>
  <official_title>The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories: A Model to Understand the Development of Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine whether oxytocin and certain polygenic risk scores
      affect the development of intrusive memories, a cardinal symptom of PTSD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Intrusive Memories in the following four days after the intervention</measure>
    <time_frame>four consecutive days</time_frame>
    <description>Influence of oxytocin on the development of intrusive memories measured with an intrusion diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noradrenergic System (measured with salivary alpha-amylase - u/ml)</measure>
    <time_frame>Day 1</time_frame>
    <description>Influence of oxytocin on the noradrenergic system measured with salivary alpha-amylase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic-pituitary-adrenal (HPA) axis (measured with salivary cortisol - nmol/L)</measure>
    <time_frame>Day 1</time_frame>
    <description>Influence of oxytocin on the HPA-axis measured with salivary cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polygenic Risk Score</measure>
    <time_frame>four consecutive days</time_frame>
    <description>Influence of polygenic risk score on development of intrusive memories</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intrusive Memories</condition>
  <arm_group>
    <arm_group_label>Oxytocin and trauma film paradigm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Oxytocin nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and trauma film paradigm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebos</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Drug: Oxytocin nasal spray</description>
    <arm_group_label>Oxytocin and trauma film paradigm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo nasal spray</description>
    <arm_group_label>Placebo and trauma film paradigm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy female volunteers

          -  German on a native level

        Exclusion Criteria:

          -  former or present disorder according to the Diagnostic and Statistical Manual of
             Mental Disorders 5 (DSM-5)

          -  any physical illnesses

          -  any medication intake (except oral contraceptive)

          -  history of traumatic experience, e.g. history of sexual abuse or rape

          -  pregnancy or lactation period

          -  follicular phase of menstrual cycle for all women not using oral contraceptives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Roepke, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tolou Maslahati, M.Sc.</last_name>
    <phone>0049 030 450 517 567</phone>
    <email>tolou.maslahati@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité- Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tolou Maslahati, M.Sc.</last_name>
      <phone>0049 30 450 517 567</phone>
      <email>tolou.maslahati@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Stefan Roepke</investigator_full_name>
    <investigator_title>Principal Investigator, PD Dr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

